26 years after shutting down lotteries, cash-strapped Himachal makes U-turn
The decision to reintroduce lotteries after over a quarter century was taken in a cabinet meeting on July 31. The recommendation came from a cabinet sub-committee set up to give suggestions to boost state revenue.
The move seems to be inspired by other states that run lotteries. Neighbouring Punjab earned Rs 235 crore through sale of lottery tickets during the 2024-25 fiscal while the tiny state of Sikkim made Rs 30 crore.
Kerala tops the list - the southern state earned a jaw-dropping Rs 13,582 crore last fiscal. Himachal, which is finding it difficult to meet the expenses of rebuilding the damage caused by this year's landslides and flash floods, hopes to mop up some much-needed funds this way.
"Many states earn through lotteries. You will be surprised to know how much Kerala earns. Himachal Pradesh govt has decided to restart the lottery system after a recommendation was made by a cabinet sub-committee," said industries minister Harshwardhan Chauhan.
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Switch to UnionBank Rewards Card
UnionBank Credit Card
Apply Now
Undo
by Taboola
by Taboola
"We will follow the tender process to run lotteries in Himachal Pradesh, just as other states do."
The decision to reintroduce lotteries in Himachal has come at a time when the state's debt stands at a back-breaking Rs 1,04,729 crore, and the per capita debt has reached Rs 1.17 lakh, the second highest after Arunachal Pradesh. To make the financial situation even worse, the revenue deficit grant, financial assistance from the Centre, has come down from Rs 6,258 crore in 2024 to Rs 3,257 crore in 2025, and GST compensation has been stopped by the Union govt.
Govt is expected to introduce the bill on lotteries in the monsoon session of assembly, beginning Aug 18.Himachal banned lotteries, both state-run and from outside, in 1999 during Prem Kumar Dhumal's tenure as chief minister.
Lotteries are legal in 13 states - Punjab, Kerala, Madhya Pradesh, Maharashtra, Goa, Bengal, Mizoram, Nagaland, Sikkim, Manipur, Arunachal Pradesh, Meghalaya, and Assam.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
18 minutes ago
- Indian Express
Tata Sons-backed Tata Capital Ltd files for IPO
Tata Sons-backed non-banking financial company (NBFC), Tata Capital Ltd, filed draft papers on Monday for an initial public offering (IPO). Tata Capital's IPO consists of a combination of fresh issuance and an offer for sale (OFS), amounting to approximately 47.58 crore equity shares. The company will be issuing up to 21 crore new shares and the existing shareholders are looking to offload up to 26.58 crore shares. Tata Sons Private Ltd, the promoter of the company, is planning to sell up to 23 crore shares in the IPO, while International Finance Corporation (IFC) has proposed to sell up to 3.58 crore shares. The issue size is estimated at around Rs 17,000 crore, as per Prime Database. The shares will be issued at a face value of Rs 10 per share. The company will use the proceeds from the fresh issue to augment its tier-1 capital base to meet its future capital requirement, including onward lending. Tata Capital is the third largest diversified NBFC in the country. The Reserve Bank of India has classified it as a systemically important NBFC, which requires stricter regulatory adherence. As per the RBI regulations, Tata Capital is required to be listed by the end of September. Tata Capital, the flagship financial services company of the Tata Group, is a subsidiary of Tata Sons Private Limited. It is primarily engaged in the lending business which comprises retail finance, SME finance and corporate finance. Tata Capital's consolidated book size increased to Rs 2,21,950.37 crore as at March 31, 2025 from Rs 1,57,760.55 crore as at March 31, 2024. During FY25, it recorded consolidated total income of Rs 28,369.87 crore as against Rs 18,198.38 crore in FY24, an increase of about 55.89 per cent. On a standalone basis, Tata Capital's recorded gross income of Rs 21,940.08 crore in FY2024-25, compared to Rs 13,309.11 crore in FY24. Profit after tax during the year was Rs 2,594.28 crore as against Rs 2,492.45 crore.
The Hindu
18 minutes ago
- The Hindu
Do not politicise my meeting with Stalin, says O. Panneerselvam
Former Chief Minister O. Panneerselvam on Monday rejected speculations about his likely association with the ruling DMK and further maintained his objective was to form Amma's government in the 2026 Assembly poll. He clarified that his recent comments on the Centre not releasing funds for Tamil Nadu under the Samagra Shiksha programme were not new, and he had flagged this as early as in August 2024. In a statement, Mr. Panneerselvam termed as 'indecent' the attempts by some to politicise his visit to Mr. Stalin's residence. 'The meeting was not related to politics,' he contended.'It is in the culture of the Tamils to visit and enquire about the well-being of someone, who has been under treatment in a hospital and has returned home, and to extend condolences if there is a loss in the family,' he said in a statement. Recalling his visit to the Chief Minister's residence, Mr. Panneerselvam explained that he visited only to enquire about the health of Mr. Stalin and express condolences over the passing of the latter's brother M.K. Muthu. He also rejected contentions and speculations which termed him as 'DMK's Team B', and he was about to forge an alliance with the DMK and maintained there was 'not even an iota of truth in it'. He recalled in June that he had condemned the Hindu Munnani over remarks made against late leaders Periyar E.V. Ramasamy and C.N. Annadurai. 'I have also condemned former BJP leaders who criticised Amma [former CM Jayalalithaa]. I have also recorded my support for the two-language policy,' he asserted. Mr. Panneerselvam added: 'I also directed to vote against the Waqf (Amendment) Bill in the Rajya Sabha. Irrespective of wherever I am, I will walk on the path laid down by Amma for the rights and welfare of the people of Tamil Nadu.'
&w=3840&q=100)
Business Standard
18 minutes ago
- Business Standard
Aurobindo Pharma Q1 PAT falls 10% on drop in API sales, US market revenue
Aurobindo Pharma on Monday reported a 10.2% year-on-year (Y-o-Y) drop in consolidated profit after tax (PAT) for the June quarter (Q1 FY26), which stood at Rs 824 crore. The decline was attributed to a drop in sales in its active pharmaceutical ingredients (API) business and the United States (US) market. The Hyderabad-based drugmaker had recorded a net profit of Rs 918 crore in Q1 FY25. The company stated that its API business was affected by pricing pressures and geopolitical tensions, with revenues for the segment falling by 16% Y-o-Y to Rs 916 crore in Q1 FY26. However, the drugmaker recorded a 4% Y-o-Y rise in revenue from operations, reaching Rs 7,868 crore in the June quarter, up from Rs 7,567 crore in Q1 FY25. This increase was primarily driven by a 7.4% Y-o-Y rise in the drugmaker's formulations business revenue, which contributes around 85% of the company's overall revenue. Aurobindo Pharma saw an 18% Y-o-Y revenue growth in European markets, which stood at Rs 2,338 crore, driven by a strong performance across all key markets. Similarly, revenue from growth markets formulations increased by 8.8% Y-o-Y to Rs 772 crore in the June quarter, compared to Rs 709 crore in the same period last year. However, the company's US formulations business, which accounts for 44% of its revenue, saw a marginal 1.9% Y-o-Y dip in sales, from Rs 3,555 crore in Q1 FY25 to Rs 3,488 crore in Q1 FY26. According to the company's regulatory filing, the decline in US revenue was primarily due to a significant reduction in sales of the anti-cancer medication lenalidomide. Commenting on the company's performance, K. Nithyananda Reddy, Vice Chairman and Managing Director of Aurobindo Pharma, said that the company has started FY26 steadily, with its European business maintaining strong growth momentum and the core US business showing resilience despite temporary challenges from destocking and seasonal dynamics. The company announced its results after market hours. On Monday, Aurobindo Pharma's shares rose marginally by 1.04%, ending the day's trade at Rs 1,090.90 apiece on the exchanges.
